The Pharmaceutical Journal’s CPD articles are peer-reviewed and have been designed to meet specific learning objectives relevant to clinical practice. As part of our aim to support members and pharmacy professionals undergoing revalidation, we are improving our CPD modules. Up until now, our CPD modules have featured 15 ‘true or false’ statements. However, from September 2019* all CPD articles will instead be accompanied by 15 single best answer (SBA) questions with five possible answers, where only one is correct. These questions will all be written by our expert authors.
An example of the new format is included below.
An example of the new ‘single best answer’ question format in The Pharmaceutical Journal’s CPD modules
1. Selective serotonin re-uptake inhibitors (SSRIs) are the most widely prescribed type of antidepressants and are generally well tolerated, but they are not free from side effects. Which of the following is not a common side effect associated with SSRI use?
b. Increased agitation
e. Suicidal ideation
Although all the options provided are possible side effects from SSRIs, suicidal ideation is an uncommon side effect and therefore the appropriate answer to this question.
This change will not only improve the way you can test your knowledge through our articles, but it also brings our assessments in-line with undergraduate and pre-registration examinations, as well as Pharmaceutical Press products, ONtrack, Pharmacy Learning Complete and Pharmacy Registration Assessment Questions (PRAQ) books.
*Please note that all modules published prior to September 2019 will follow the old style of 15 true or false questions.